Michelle T Long1, Na Wang1, Martin G Larson1, Gary F Mitchell1, Joseph Palmisano1, Ramachandran S Vasan1, Udo Hoffmann1, Elizabeth K Speliotes1, Joseph A Vita1, Emelia J Benjamin1, Caroline S Fox1, Naomi M Hamburg2. 1. From the Division of Gastroenterology, Boston Medical Center (M.T.L.), Section of Preventive Medicine, Department of Medicine (R.S.V.), Evans Department of Medicine, Whitaker Cardiovascular Institute and Cardiology Section (R.S.V., J.A.V., N.M.H.), Boston University School of Medicine, MA; National Heart, Lung, and Blood Institute's Framingham Heart Study, MA (M.T.L., M.G.L., R.S.V., E.J.B., C.S.F.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiovascular Engineering, Inc, Norwood, MA (G.F.M.); Data Coordinating Center (J.P., N.W.), Department of Epidemiology (E.J.B.), Boston University School of Public Health, MA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston (U.H.); Division of Gastroenterology, Department of Internal Medicine, and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor (E.K.S.); and Division of Endocrinology, Hypertension, and Metabolism, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (C.S.F.). 2. From the Division of Gastroenterology, Boston Medical Center (M.T.L.), Section of Preventive Medicine, Department of Medicine (R.S.V.), Evans Department of Medicine, Whitaker Cardiovascular Institute and Cardiology Section (R.S.V., J.A.V., N.M.H.), Boston University School of Medicine, MA; National Heart, Lung, and Blood Institute's Framingham Heart Study, MA (M.T.L., M.G.L., R.S.V., E.J.B., C.S.F.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiovascular Engineering, Inc, Norwood, MA (G.F.M.); Data Coordinating Center (J.P., N.W.), Department of Epidemiology (E.J.B.), Boston University School of Public Health, MA; Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston (U.H.); Division of Gastroenterology, Department of Internal Medicine, and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor (E.K.S.); and Division of Endocrinology, Hypertension, and Metabolism, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (C.S.F.). nhamburg@bu.edu.
Abstract
OBJECTIVE: Patients with nonalcoholic fatty liver disease (NAFLD) have an increased risk of cardiovascular disease; however, it is not known whether NAFLD contributes to cardiovascular disease independent of established risk factors. We examined the association between NAFLD and vascular function. APPROACH AND RESULTS: We conducted a cross-sectional study of 2284 Framingham Heart Study participants without overt cardiovascular disease who had liver fat attenuation measured on computed tomography and who had measurements of vascular function and covariates. We evaluated the association between NAFLD and vascular function using multivariable partial correlations adjusting for age, sex, cohort, smoking, diabetes mellitus, hyperlipidemia, hypertension, body mass index, and visceral adipose tissue. The prevalence of NAFLD in our sample (mean age, 52±12 years; 51.4% women) was 15.3%. In age-, sex-, and cohort-adjusted analyses, greater liver fat was modestly associated with lower flow-mediated dilation (r=-0.05; P=0.02), lower peripheral arterial tonometry ratio (r=-0.20; P<0.0001), higher carotid-femoral pulse wave velocity (r=0.13; P<0.0001), and higher mean arterial pressure (r=0.11; P<0.0001). In multivariable-adjusted models, NAFLD remained associated with higher mean arterial pressure (r=0.06; P=0.005) and lower peripheral arterial tonometry ratio (r=-0.12; P<0.0001). The association between NAFLD and peripheral arterial tonometry ratio persisted after further adjustment for body mass index and visceral adipose tissue. CONCLUSIONS: For multiple measures of vascular function, the relationship with NAFLD appeared largely determined by shared cardiometabolic risk factors. The persistent relationship with reduced peripheral arterial tonometry response beyond established risk factors suggests that NAFLD may contribute to microvascular dysfunction.
OBJECTIVE:Patients with nonalcoholic fatty liver disease (NAFLD) have an increased risk of cardiovascular disease; however, it is not known whether NAFLD contributes to cardiovascular disease independent of established risk factors. We examined the association between NAFLD and vascular function. APPROACH AND RESULTS: We conducted a cross-sectional study of 2284 Framingham Heart Study participants without overt cardiovascular disease who had liver fat attenuation measured on computed tomography and who had measurements of vascular function and covariates. We evaluated the association between NAFLD and vascular function using multivariable partial correlations adjusting for age, sex, cohort, smoking, diabetes mellitus, hyperlipidemia, hypertension, body mass index, and visceral adipose tissue. The prevalence of NAFLD in our sample (mean age, 52±12 years; 51.4% women) was 15.3%. In age-, sex-, and cohort-adjusted analyses, greater liver fat was modestly associated with lower flow-mediated dilation (r=-0.05; P=0.02), lower peripheral arterial tonometry ratio (r=-0.20; P<0.0001), higher carotid-femoral pulse wave velocity (r=0.13; P<0.0001), and higher mean arterial pressure (r=0.11; P<0.0001). In multivariable-adjusted models, NAFLD remained associated with higher mean arterial pressure (r=0.06; P=0.005) and lower peripheral arterial tonometry ratio (r=-0.12; P<0.0001). The association between NAFLD and peripheral arterial tonometry ratio persisted after further adjustment for body mass index and visceral adipose tissue. CONCLUSIONS: For multiple measures of vascular function, the relationship with NAFLD appeared largely determined by shared cardiometabolic risk factors. The persistent relationship with reduced peripheral arterial tonometry response beyond established risk factors suggests that NAFLD may contribute to microvascular dysfunction.
Authors: Elizabeth K Speliotes; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; James B Meigs; Dushyant V Sahani; Joel N Hirschhorn; Christopher J O'Donnell; Caroline S Fox Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Joseph Yeboah; Aaron R Folsom; Gregory L Burke; Craig Johnson; Joseph F Polak; Wendy Post; Joao A Lima; John R Crouse; David M Herrington Journal: Circulation Date: 2009-07-27 Impact factor: 29.690
Authors: Naomi M Hamburg; Joseph Palmisano; Martin G Larson; Lisa M Sullivan; Birgitta T Lehman; Ramachandran S Vasan; Daniel Levy; Gary F Mitchell; Joseph A Vita; Emelia J Benjamin Journal: Hypertension Date: 2011-01-24 Impact factor: 10.190
Authors: Gary F Mitchell; Shih-Jen Hwang; Ramachandran S Vasan; Martin G Larson; Michael J Pencina; Naomi M Hamburg; Joseph A Vita; Daniel Levy; Emelia J Benjamin Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: Zachary P Fricker; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Emelia J Benjamin; Michelle T Long Journal: Clin Gastroenterol Hepatol Date: 2018-11-23 Impact factor: 11.382
Authors: Frank T Spradley; Jillian A Smith; Barbara T Alexander; Christopher D Anderson Journal: Am J Physiol Endocrinol Metab Date: 2018-03-06 Impact factor: 4.310
Authors: S Lefere; F Van de Velde; L Devisscher; M Bekaert; S Raevens; X Verhelst; Y Van Nieuwenhove; M Praet; A Hoorens; C Van Steenkiste; H Van Vlierberghe; B Lapauw; A Geerts Journal: Int J Obes (Lond) Date: 2017-05-02 Impact factor: 5.095
Authors: Wenyuan Li; Kirsten S Dorans; Elissa H Wilker; Mary B Rice; Michelle T Long; Joel Schwartz; Brent A Coull; Petros Koutrakis; Diane R Gold; Caroline S Fox; Murray A Mittleman Journal: Am J Epidemiol Date: 2017-10-01 Impact factor: 4.897
Authors: Galit Weinstein; Shira Zelber-Sagi; Sarah R Preis; Alexa S Beiser; Charles DeCarli; Elizabeth K Speliotes; Claudia L Satizabal; Ramachandran S Vasan; Sudha Seshadri Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302